Caribou 10-Q: $94.8M Cash, $26.6M Q3 Loss, Nasdaq Bid-Price Deficiency Disclosed
CRBU is trading near its 52-week low of $0.403 (0.5% above the low).
Summary
Caribou's Q3 10-Q shows $94.8M in cash against a $26.6M quarterly loss and $15.0M-$19.0M of restructuring charges still ahead, while disclosing the stock has sat below Nasdaq's $1.00 minimum bid since the October strategic-alternatives announcement.
Key Events · Earnings and Guidance · CRBU
-
Q3 Loss of $26.6M, Cash Down to $94.8M
GAAP net loss was $26.6 million ($0.25 per share) versus $27.5 million ($0.30) a year earlier; cash, equivalents and marketable securities fell to $94.8 million from $142.8 million at December 31, 2025.
-
Restructuring to Cost $15M-$19M
The October 2026 restructuring — severance of $10.0M-$11.0M plus $5.0M-$8.0M to wind down the ANTLER and CaMMouflage trials — is mostly unrecognized and expected in Q4 2026, so it is not in the Q3 figures.
-
Nasdaq $1.00 Bid-Price Deficiency
The 10-Q states the stock has consistently traded below Nasdaq's $1.00 minimum bid since the October 6, 2026 announcement, and that a reverse split may be needed; delisting would push the shares under penny-stock rules.
-
ATM Was the Only New Capital
Caribou sold 11,565,913 shares in the first nine months at an average $2.01 for $23.3 million gross ($22.8 million net), including 1,480,869 shares at $1.84 for $2.7 million in Q3; $72.5 million remains available under the program.
Analysis · CRBU · Life Sciences
The Q3 numbers were already out via this morning's 8-K, but the full 10-Q carries two things the press release did not. First, the cash math: $94.8M at September 30 against $72.3M of nine-month operating burn, with $15.0M-$19.0M of restructuring costs still to come, mostly in Q4 — the runway is real but shrinking fast while the board shops for a merger, sale or liquidation. Second, the company now says its stock has traded consistently below Nasdaq's $1.00 minimum bid since the October 6 announcement, which puts a delisting clock and a possible reverse split on the table. The ATM was the only source of new money: 11.6M shares sold for $23.3M gross in the first nine months, at average prices far above today's $0.405, and $72.5M remains available on the program.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRBU was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.2M. The 52-week trading range was $0.40 to $2.49. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.